While supplies of popular obesity treatments like Wegovy and Zepbound are improving, access remains restricted due to varying insurance coverage. Many employers are cutting back on these benefits, and Medicare does not currently cover obesity treatment drugs. Prices can exceed hundreds of dollars monthly, making them unattainable for many without insurance. Patients often find their weight management reliant on their coverage sustainability, which can change unexpectedly, as illustrated by one man's experience after losing Medicaid coverage. Approximately 44% of large U.S. employers provided obesity drug coverage last year, emphasizing the need for more consistent support in this area.
"There are a lot of people right now who want access to the medication and can't get it," said Katherine Hempstead, highlighting the challenges of coverage for obesity treatments.
"I couldn't control the eating, he said. All the noise came back," Paul Mack shared his struggle after losing coverage for Wegovy, indicating the importance of consistent medication.
Collection
[
|
...
]